{"product_id":"thymosin-alpha-1-10mg-vial","title":"Thymosin alpha-1 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                     \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"822\" data-start=\"64\"\u003e\u003cstrong\u003eThymosin α1 \u003c\/strong\u003eis a \u003cstrong data-end=\"149\" data-start=\"114\"\u003e28–amino-acid synthetic peptide\u003c\/strong\u003e originally isolated from thymic extracts (thymosin fraction 5). It acts as a \u003cstrong data-end=\"260\" data-start=\"227\"\u003ehost-directed immunomodulator\u003c\/strong\u003e, enhancing \u003cstrong data-end=\"312\" data-start=\"272\"\u003eantigen presentation (DC maturation)\u003c\/strong\u003e, \u003cstrong data-end=\"343\" data-start=\"314\"\u003eT-cell priming (Th1 bias)\u003c\/strong\u003e, \u003cstrong data-end=\"369\" data-start=\"345\"\u003eNK-cell cytotoxicity\u003c\/strong\u003e, and re-balancing dysregulated cytokine networks. Mechanistically it interfaces with \u003cstrong data-end=\"523\" data-start=\"455\"\u003epattern-recognition pathways (e.g., TLR2\/7\/9 on dendritic cells)\u003c\/strong\u003e and \u003cstrong data-end=\"566\" data-start=\"528\"\u003eintracellular NF-κB\/IRF signalling\u003c\/strong\u003e, improving antiviral and antitumour responses while limiting hyper-inflammation. Thymosin α1 is \u003cstrong data-end=\"707\" data-start=\"663\"\u003eapproved in several countries (ex-US\/EU)\u003c\/strong\u003e—historically for \u003cstrong data-end=\"750\" data-start=\"725\"\u003echronic hepatitis B\/C\u003c\/strong\u003e and adjunctive immunotherapy—\u003cstrong data-end=\"800\" data-start=\"780\"\u003enot FDA-approved\u003c\/strong\u003e in the United States.\u003c\/p\u003e\n\u003chr data-end=\"827\" data-start=\"824\"\u003e\n\u003ch3 data-end=\"891\" data-start=\"829\"\u003eAdditional Benefits of Thymosin α1 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3482\" data-start=\"893\"\u003e\n\u003cthead data-end=\"921\" data-start=\"893\"\u003e\n\u003ctr data-end=\"921\" data-start=\"893\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"903\" data-start=\"893\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"921\" data-start=\"903\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3482\" data-start=\"932\"\u003e\n\u003ctr data-end=\"1221\" data-start=\"932\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"984\" data-start=\"932\"\u003e\u003cstrong data-end=\"983\" data-start=\"934\"\u003e1 Antiviral host defence (HBV\/HCV and beyond)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1221\" data-start=\"984\"\u003eIn chronic hepatitis, Tα1 \u003cstrong data-end=\"1067\" data-start=\"1012\"\u003eimproves HBeAg seroconversion and ALT normalization\u003c\/strong\u003e and augments interferon\/NA responses; newer work explores \u003cstrong data-end=\"1133\" data-start=\"1126\"\u003eHDV\u003c\/strong\u003e and difficult-to-cure HBV phenotypes. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Journal of Hepatology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1497\" data-start=\"1222\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1248\" data-start=\"1222\"\u003e\u003cstrong data-end=\"1247\" data-start=\"1224\"\u003e2 Vaccine adjuvancy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1497\" data-start=\"1248\"\u003ePeri-vaccination courses \u003cstrong data-end=\"1328\" data-start=\"1275\"\u003eincrease seroconversion rates and antibody titres\u003c\/strong\u003e in hypo-responders (elderly, CKD, cirrhosis) and \u003cstrong data-end=\"1406\" data-start=\"1378\"\u003eenhance T-cell responses\u003c\/strong\u003e to viral and tumour antigens. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Vaccine; Human Vaccines \u0026amp; Immunotherapeutics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1781\" data-start=\"1498\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1539\" data-start=\"1498\"\u003e\u003cstrong data-end=\"1538\" data-start=\"1500\"\u003e3 Oncology (immunotherapy adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1781\" data-start=\"1539\"\u003eTα1 \u003cstrong data-end=\"1594\" data-start=\"1545\"\u003eboosts DC cross-presentation and CD8⁺ priming\u003c\/strong\u003e, showing \u003cstrong data-end=\"1666\" data-start=\"1604\"\u003esynergy with checkpoint inhibitors and chemo-immunotherapy\u003c\/strong\u003e in early trials for melanoma, HCC, and lung cancer. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cancer Immunology Research; Annals of Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2092\" data-start=\"1782\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1828\" data-start=\"1782\"\u003e\u003cstrong data-end=\"1827\" data-start=\"1784\"\u003e4 Sepsis\/critical-illness immunoparesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2092\" data-start=\"1828\"\u003eIn lymphopenic\/septic phenotypes, Tα1 \u003cstrong data-end=\"1900\" data-start=\"1868\"\u003erestores HLA-DR on monocytes\u003c\/strong\u003e, increases \u003cstrong data-end=\"1926\" data-start=\"1912\"\u003eIFN-γ\/IL-2\u003c\/strong\u003ewhile reducing \u003cstrong data-end=\"1956\" data-start=\"1942\"\u003eIL-6\/TNF-α\u003c\/strong\u003e, with signals for \u003cstrong data-end=\"2018\" data-start=\"1975\"\u003elower secondary infection and mortality\u003c\/strong\u003e in select cohorts. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Critical Care; Intensive Care Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2407\" data-start=\"2093\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2148\" data-start=\"2093\"\u003e\u003cstrong data-end=\"2147\" data-start=\"2095\"\u003e5 Respiratory infections \u0026amp; ARDS (mixed evidence)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2407\" data-start=\"2148\"\u003eObservational and small RCTs suggest \u003cstrong data-end=\"2210\" data-start=\"2187\"\u003ereduced progression\u003c\/strong\u003e in viral pneumonias when given to \u003cstrong data-end=\"2260\" data-start=\"2245\"\u003elymphopenic\u003c\/strong\u003e patients; other trials are \u003cstrong data-end=\"2299\" data-start=\"2288\"\u003eneutral\u003c\/strong\u003e, underscoring the need for \u003cstrong data-end=\"2351\" data-start=\"2327\"\u003ephenotype-guided use\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Chest; The Lancet Respiratory Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2679\" data-start=\"2408\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2443\" data-start=\"2408\"\u003e\u003cstrong data-end=\"2442\" data-start=\"2410\"\u003e6 Immunosenescence \u0026amp; frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2679\" data-start=\"2443\"\u003eShort courses \u003cstrong data-end=\"2506\" data-start=\"2459\"\u003eincrease naïve\/memory T-cell markers, TRECs\u003c\/strong\u003e, and \u003cstrong data-end=\"2531\" data-start=\"2512\"\u003eNK cytotoxicity\u003c\/strong\u003e in older adults, with \u003cstrong data-end=\"2583\" data-start=\"2554\"\u003efewer seasonal infections\u003c\/strong\u003e and better vaccine responses. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Gerontology; Mechanisms of Ageing and Development\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2966\" data-start=\"2680\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2719\" data-start=\"2680\"\u003e\u003cstrong data-end=\"2718\" data-start=\"2682\"\u003e7 Autoimmune “rebalance” (pilot)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2966\" data-start=\"2719\"\u003eBy promoting \u003cstrong data-end=\"2752\" data-start=\"2734\"\u003eTreg stability\u003c\/strong\u003e and dampening pathologic Th17\/Th2 signals, Tα1 is being explored as an \u003cstrong data-end=\"2835\" data-start=\"2824\"\u003eadjunct\u003c\/strong\u003e in autoimmune thyroid disease, IBD, and psoriasis (early-phase data). \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Immunology; Journal of Autoimmunity\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3229\" data-start=\"2967\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2999\" data-start=\"2967\"\u003e\u003cstrong data-end=\"2998\" data-start=\"2969\"\u003e8 Onco-hematology support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"3229\" data-start=\"2999\"\u003eAdjunct Tα1 \u003cstrong data-end=\"3046\" data-start=\"3013\"\u003eshortens neutropenia duration\u003c\/strong\u003e, improves \u003cstrong data-end=\"3078\" data-start=\"3057\"\u003einfection control\u003c\/strong\u003e, and may \u003cstrong data-end=\"3112\" data-start=\"3088\"\u003espeed count recovery\u003c\/strong\u003e with chemotherapy or transplant conditioning. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone Marrow Transplantation; Supportive Care in Cancer\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3482\" data-start=\"3230\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3275\" data-start=\"3230\"\u003e\u003cstrong data-end=\"3274\" data-start=\"3232\"\u003e9 Metabolic-liver disease (NAFLD\/NASH)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"3482\" data-start=\"3275\"\u003eProof-of-concept studies show \u003cstrong data-end=\"3348\" data-start=\"3307\"\u003eALT\/AST and CAP\/MRI-PDFF improvements\u003c\/strong\u003e with immune\/metabolic re-tuning; larger controlled trials are pending. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology Communications; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3487\" data-start=\"3484\"\u003e\n\u003ch2 data-end=\"3524\" data-start=\"3489\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3552\" data-start=\"3526\"\u003e2.1 Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3926\" data-start=\"3553\"\u003eTα1 engages \u003cstrong data-end=\"3577\" data-start=\"3565\"\u003eTLR2\/7\/9\u003c\/strong\u003e (context-dependent) on \u003cstrong data-end=\"3634\" data-start=\"3601\"\u003edendritic cells and monocytes\u003c\/strong\u003e, promoting \u003cstrong data-end=\"3680\" data-start=\"3646\"\u003ematuration (↑CD80\/86, ↑HLA-DR)\u003c\/strong\u003e and \u003cstrong data-end=\"3694\" data-start=\"3685\"\u003eIL-12\u003c\/strong\u003e production; this \u003cstrong data-end=\"3746\" data-start=\"3712\"\u003elicenses Th1 and CTL responses\u003c\/strong\u003e. In T cells, Tα1 enhances \u003cstrong data-end=\"3789\" data-start=\"3773\"\u003eIL-2R (CD25)\u003c\/strong\u003eexpression, \u003cstrong data-end=\"3811\" data-start=\"3802\"\u003eIFN-γ\u003c\/strong\u003e production and \u003cstrong data-end=\"3850\" data-start=\"3827\"\u003esurvival signalling\u003c\/strong\u003e, while \u003cstrong data-end=\"3896\" data-start=\"3858\"\u003etempering excessive NF-κB activity\u003c\/strong\u003e in hyper-inflammatory states.\u003c\/p\u003e\n\u003ch3 data-end=\"3955\" data-start=\"3928\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4425\" data-start=\"3957\"\u003e\n\u003cthead data-end=\"3999\" data-start=\"3957\"\u003e\n\u003ctr data-end=\"3999\" data-start=\"3957\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3967\" data-start=\"3957\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3988\" data-start=\"3967\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3999\" data-start=\"3988\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4425\" data-start=\"4014\"\u003e\n\u003ctr data-end=\"4115\" data-start=\"4014\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4037\" data-start=\"4014\"\u003eTLR→MyD88→NF-κB\/IRFs\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4088\" data-start=\"4037\"\u003eDC maturation, type-1 cytokines, antiviral genes\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4115\" data-start=\"4088\"\u003eInnate\/APC compartments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4193\" data-start=\"4116\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4135\" data-start=\"4116\"\u003eIL-12\/IFN-γ axis\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4170\" data-start=\"4135\"\u003eTh1 polarization, CTL activation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4193\" data-start=\"4170\"\u003eAdaptive T\/NK cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4281\" data-start=\"4194\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4214\" data-start=\"4194\"\u003eTreg\/Th17 balance\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4252\" data-start=\"4214\"\u003e↑ Treg stability, ↓ pathogenic Th17\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4281\" data-start=\"4252\"\u003eAutoimmunity\/inflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4353\" data-start=\"4282\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4305\" data-start=\"4282\"\u003eAntigen presentation\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4336\" data-start=\"4305\"\u003e↑ HLA-DR, cross-presentation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4353\" data-start=\"4336\"\u003eDCs\/monocytes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4425\" data-start=\"4354\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4377\" data-start=\"4354\"\u003eNK effector pathways\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4413\" data-start=\"4377\"\u003e↑ Perforin\/Granzyme, cytotoxicity\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4425\" data-start=\"4413\"\u003eNK cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4430\" data-start=\"4427\"\u003e\n\u003ch2 data-end=\"4454\" data-start=\"4432\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4936\" data-start=\"4456\"\u003e\n\u003cli data-end=\"4520\" data-start=\"4456\"\u003e\n\u003cp data-end=\"4520\" data-start=\"4458\"\u003e\u003cstrong data-end=\"4468\" data-start=\"4458\"\u003eRoute:\u003c\/strong\u003e Subcutaneous is standard; IV used in some trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4684\" data-start=\"4521\"\u003e\n\u003cp data-end=\"4684\" data-start=\"4523\"\u003e\u003cstrong data-end=\"4543\" data-start=\"4523\"\u003eAbsorption \u0026amp; t½:\u003c\/strong\u003e Rapid absorption; \u003cstrong data-end=\"4595\" data-start=\"4562\"\u003eterminal half-life ~1.5–2.0 h\u003c\/strong\u003e (SC); pharmacodynamic effects \u003cstrong data-end=\"4646\" data-start=\"4626\"\u003eoutlast exposure\u003c\/strong\u003e via transcriptional re-programming.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4866\" data-start=\"4685\"\u003e\n\u003cp data-end=\"4866\" data-start=\"4687\"\u003e\u003cstrong data-end=\"4731\" data-start=\"4687\"\u003eDosing paradigms (by indication\/trials):\u003c\/strong\u003e \u003cstrong data-end=\"4753\" data-start=\"4732\"\u003e1.6 mg SC 2×\/week\u003c\/strong\u003e (chronic hepatitis) for months; \u003cstrong data-end=\"4798\" data-start=\"4786\"\u003edaily SC\u003c\/strong\u003e in short ICU\/oncology courses; peri-vaccination \u003cstrong data-end=\"4863\" data-start=\"4847\"\u003eshort cycles\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4936\" data-start=\"4867\"\u003e\n\u003cp data-end=\"4936\" data-start=\"4869\"\u003e\u003cstrong data-end=\"4883\" data-start=\"4869\"\u003eClearance:\u003c\/strong\u003e Peptidase degradation; no CYP interactions expected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4941\" data-start=\"4938\"\u003e\n\u003ch2 data-end=\"4988\" data-start=\"4943\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"5023\" data-start=\"4990\"\u003e4.1 Chronic Viral Hepatitis\u003c\/h3\u003e\n\u003cp data-end=\"5239\" data-start=\"5024\"\u003eMultiple RCTs (legacy and modern) show \u003cstrong data-end=\"5111\" data-start=\"5063\"\u003eimproved biochemical and serologic responses\u003c\/strong\u003e with Tα1 alone or combined with interferon or nucleos(t)ide analogues; durability varies by \u003cstrong data-end=\"5238\" data-start=\"5204\"\u003egenotype and baseline immunity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-end=\"5259\" data-start=\"5241\"\u003e4.2 Oncology\u003c\/h3\u003e\n\u003cp data-end=\"5469\" data-start=\"5260\"\u003eTα1 \u003cstrong data-end=\"5304\" data-start=\"5264\"\u003eenhances tumour antigen presentation\u003c\/strong\u003e and \u003cstrong data-end=\"5330\" data-start=\"5309\"\u003eCD8⁺ infiltration\u003c\/strong\u003e; early clinical programmes suggest \u003cstrong data-end=\"5387\" data-start=\"5366\"\u003eadditive efficacy\u003c\/strong\u003ewith \u003cstrong data-end=\"5407\" data-start=\"5393\"\u003ePD-1\/PD-L1\u003c\/strong\u003e inhibitors and \u003cstrong data-end=\"5431\" data-start=\"5423\"\u003eTACE\u003c\/strong\u003e in HCC, with acceptable tolerability.\u003c\/p\u003e\n\u003ch3 data-end=\"5501\" data-start=\"5471\"\u003e4.3 Sepsis\/Critical Care\u003c\/h3\u003e\n\u003cp data-end=\"5704\" data-start=\"5502\"\u003eSignals for \u003cstrong data-end=\"5543\" data-start=\"5514\"\u003ereversal of immunoparesis\u003c\/strong\u003e (↑ mHLA-DR, ↑ lymphocyte counts) and \u003cstrong data-end=\"5611\" data-start=\"5581\"\u003elower secondary infections\u003c\/strong\u003e in phenotyped (lymphopenic) patients; heterogeneous results emphasize \u003cstrong data-end=\"5703\" data-start=\"5682\"\u003epatient selection\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-end=\"5736\" data-start=\"5706\"\u003e4.4 Vaccinology \u0026amp; Ageing\u003c\/h3\u003e\n\u003cp data-end=\"5901\" data-start=\"5737\"\u003eConsistent \u003cstrong data-end=\"5768\" data-start=\"5748\"\u003eadjuvant effects\u003c\/strong\u003e in hypo-responders (older adults, CKD, cirrhosis), including \u003cstrong data-end=\"5861\" data-start=\"5830\"\u003ehigher seroprotection rates\u003c\/strong\u003eand \u003cstrong data-end=\"5900\" data-start=\"5866\"\u003emore durable cellular immunity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-end=\"6083\" data-start=\"5903\"\u003e\n\u003cp data-end=\"6083\" data-start=\"5905\"\u003e\u003cstrong data-end=\"5931\" data-start=\"5905\"\u003eEvidence quality note:\u003c\/strong\u003e Contemporary, well-controlled multicentre trials exist in hepatology and oncology; critical-care and NAFLD data are \u003cstrong data-end=\"6060\" data-start=\"6048\"\u003eemerging\u003c\/strong\u003e and \u003cstrong data-end=\"6082\" data-start=\"6065\"\u003eheterogeneous\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"6088\" data-start=\"6085\"\u003e\n\u003ch2 data-end=\"6123\" data-start=\"6090\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6703\" data-start=\"6125\"\u003e\n\u003cthead data-end=\"6163\" data-start=\"6125\"\u003e\n\u003ctr data-end=\"6163\" data-start=\"6125\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6133\" data-start=\"6125\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"6145\" data-start=\"6133\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"6163\" data-start=\"6145\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6703\" data-start=\"6178\"\u003e\n\u003ctr data-end=\"6297\" data-start=\"6178\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6213\" data-start=\"6178\"\u003e\u003cstrong data-end=\"6212\" data-start=\"6180\"\u003eCheckpoint-inhibitor adjunct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6257\" data-start=\"6213\"\u003eBolster priming, reduce immune exhaustion\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6297\" data-start=\"6257\"\u003ePhase 2 signals; larger RCTs ongoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6410\" data-start=\"6298\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6333\" data-start=\"6298\"\u003e\u003cstrong data-end=\"6332\" data-start=\"6300\"\u003ePhenotype-guided sepsis care\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6371\" data-start=\"6333\"\u003eTreat \u003cstrong data-end=\"6370\" data-start=\"6341\"\u003elymphopenic immunoparesis\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6410\" data-start=\"6371\"\u003ePrecision-trial designs in progress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6488\" data-start=\"6411\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6428\" data-start=\"6411\"\u003e\u003cstrong data-end=\"6427\" data-start=\"6413\"\u003eNAFLD\/NASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6466\" data-start=\"6428\"\u003eImmune-metabolic re-tuning of liver\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6488\" data-start=\"6466\"\u003ePilot RCTs planned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6589\" data-start=\"6489\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6522\" data-start=\"6489\"\u003e\u003cstrong data-end=\"6521\" data-start=\"6491\"\u003eTransplant infectious risk\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6568\" data-start=\"6522\"\u003eImprove antiviral defence without rejection\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6589\" data-start=\"6568\"\u003eEarly feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6703\" data-start=\"6590\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6621\" data-start=\"6590\"\u003e\u003cstrong data-end=\"6620\" data-start=\"6592\"\u003eElderly vaccine response\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6655\" data-start=\"6621\"\u003eRaise seroconversion\/durability\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6703\" data-start=\"6655\"\u003ePositive small trials; policy studies needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6708\" data-start=\"6705\"\u003e\n\u003ch2 data-end=\"6739\" data-start=\"6710\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"7323\" data-start=\"6741\"\u003e\n\u003cli data-end=\"6839\" data-start=\"6741\"\u003e\n\u003cp data-end=\"6839\" data-start=\"6743\"\u003e\u003cstrong data-end=\"6754\" data-start=\"6743\"\u003eCommon:\u003c\/strong\u003e Mild \u003cstrong data-end=\"6787\" data-start=\"6760\"\u003einjection-site erythema\u003c\/strong\u003e, \u003cstrong data-end=\"6810\" data-start=\"6789\"\u003etransient fatigue\u003c\/strong\u003e, \u003cstrong data-end=\"6824\" data-start=\"6812\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-end=\"6836\" data-start=\"6826\"\u003enausea\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6979\" data-start=\"6840\"\u003e\n\u003cp data-end=\"6979\" data-start=\"6842\"\u003e\u003cstrong data-end=\"6861\" data-start=\"6842\"\u003eImmune effects:\u003c\/strong\u003e Generally \u003cstrong data-end=\"6893\" data-start=\"6872\"\u003eimmunorestorative\u003c\/strong\u003e, not broadly immunosuppressive; monitor in \u003cstrong data-end=\"6951\" data-start=\"6937\"\u003eautoimmune\u003c\/strong\u003econditions (rare flares).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7075\" data-start=\"6980\"\u003e\n\u003cp data-end=\"7075\" data-start=\"6982\"\u003e\u003cstrong data-end=\"6994\" data-start=\"6982\"\u003eHepatic:\u003c\/strong\u003e Typically \u003cstrong data-end=\"7017\" data-start=\"7005\"\u003eimproves\u003c\/strong\u003e rather than worsens transaminases in hepatitis cohorts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7169\" data-start=\"7076\"\u003e\n\u003cp data-end=\"7169\" data-start=\"7078\"\u003e\u003cstrong data-end=\"7100\" data-start=\"7078\"\u003eDrug interactions:\u003c\/strong\u003e \u003cstrong data-end=\"7113\" data-start=\"7101\"\u003eAdditive\u003c\/strong\u003e with interferons and antivirals; no known CYP issues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7323\" data-start=\"7170\"\u003e\n\u003cp data-end=\"7323\" data-start=\"7172\"\u003e\u003cstrong data-end=\"7196\" data-start=\"7172\"\u003eSpecial populations:\u003c\/strong\u003e Use caution in \u003cstrong data-end=\"7226\" data-start=\"7212\"\u003etransplant\u003c\/strong\u003e (balance infection risk vs rejection), \u003cstrong data-end=\"7279\" data-start=\"7266\"\u003epregnancy\u003c\/strong\u003e, and \u003cstrong data-end=\"7298\" data-start=\"7285\"\u003epediatric\u003c\/strong\u003esettings outside trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7354\" data-start=\"7325\"\u003e\u003cstrong data-end=\"7354\" data-start=\"7325\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7921\" data-start=\"7356\"\u003e\n\u003cthead data-end=\"7474\" data-start=\"7356\"\u003e\n\u003ctr data-end=\"7474\" data-start=\"7356\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7366\" data-start=\"7356\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7396\" data-start=\"7366\"\u003e\u003cstrong data-end=\"7395\" data-start=\"7368\"\u003eThymosin α1 (synthetic)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7428\" data-start=\"7396\"\u003e\u003cstrong data-end=\"7427\" data-start=\"7398\"\u003eThymalin (bovine extract)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"7474\" data-start=\"7428\"\u003e\u003cstrong data-end=\"7472\" data-start=\"7430\"\u003eInterferon-α (for HBV\/HCV, historical)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7921\" data-start=\"7493\"\u003e\n\u003ctr data-end=\"7579\" data-start=\"7493\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7507\" data-start=\"7493\"\u003eComposition\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7534\" data-start=\"7507\"\u003e\u003cstrong data-end=\"7533\" data-start=\"7509\"\u003eSingle 28-aa peptide\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7558\" data-start=\"7534\"\u003eMulti-peptide mixture\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7579\" data-start=\"7558\"\u003eCytokine biologic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7694\" data-start=\"7580\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7601\" data-start=\"7580\"\u003eImmunologic action\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7633\" data-start=\"7601\"\u003e\u003cstrong data-end=\"7632\" data-start=\"7603\"\u003eHost-directed restoration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7658\" data-start=\"7633\"\u003eBroad immunocorrection\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7694\" data-start=\"7658\"\u003ePotent antiviral\/immunostimulant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7816\" data-start=\"7695\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7708\" data-start=\"7695\"\u003eAE profile\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7743\" data-start=\"7708\"\u003e\u003cstrong data-end=\"7742\" data-start=\"7710\"\u003eMild, injection-site\/fatigue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7771\" data-start=\"7743\"\u003eVariable; extract-related\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7816\" data-start=\"7771\"\u003eFlu-like syndrome, depression, cytopenias\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7921\" data-start=\"7817\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7840\" data-start=\"7817\"\u003eRegulatory footprint\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7864\" data-start=\"7840\"\u003e\u003cstrong data-end=\"7863\" data-start=\"7842\"\u003eApproved ex-US\/EU\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7884\" data-start=\"7864\"\u003eRegional (RU\/CIS)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7921\" data-start=\"7884\"\u003eGlobal (historical hepatitis use)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7926\" data-start=\"7923\"\u003e\n\u003ch2 data-end=\"7954\" data-start=\"7928\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"8337\" data-start=\"7956\"\u003e\n\u003cli data-end=\"8132\" data-start=\"7956\"\u003e\n\u003cp data-end=\"8132\" data-start=\"7958\"\u003e\u003cstrong data-end=\"7982\" data-start=\"7958\"\u003eApproved (ex-US\/EU):\u003c\/strong\u003e Adjunct treatment for \u003cstrong data-end=\"8024\" data-start=\"8005\"\u003echronic HBV\/HCV\u003c\/strong\u003e, \u003cstrong data-end=\"8048\" data-start=\"8026\"\u003eimmune restoration\u003c\/strong\u003e, and \u003cstrong data-end=\"8075\" data-start=\"8054\"\u003evaccine adjuvancy\u003c\/strong\u003ein multiple countries (e.g., parts of Asia, ME\/LatAm).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8241\" data-start=\"8133\"\u003e\n\u003cp data-end=\"8241\" data-start=\"8135\"\u003e\u003cstrong data-end=\"8156\" data-start=\"8135\"\u003eUnited States\/EU:\u003c\/strong\u003e \u003cstrong data-end=\"8181\" data-start=\"8157\"\u003eNot FDA\/EMA-approved\u003c\/strong\u003e; accessible only via clinical trials or special pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8337\" data-start=\"8242\"\u003e\n\u003cp data-end=\"8337\" data-start=\"8244\"\u003e\u003cstrong data-end=\"8256\" data-start=\"8244\"\u003eQuality:\u003c\/strong\u003e Use \u003cstrong data-end=\"8290\" data-start=\"8261\"\u003eGMP-certified thymalfasin\u003c\/strong\u003e; avoid unregulated “research peptide” sources.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8342\" data-start=\"8339\"\u003e\n\u003ch2 data-end=\"8367\" data-start=\"8344\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"9032\" data-start=\"8369\"\u003e\n\u003cli data-end=\"8524\" data-start=\"8369\"\u003e\n\u003cp data-end=\"8524\" data-start=\"8371\"\u003e\u003cstrong data-end=\"8398\" data-start=\"8371\"\u003ePhenotype-driven trials\u003c\/strong\u003e in \u003cstrong data-end=\"8424\" data-start=\"8402\"\u003elymphopenic sepsis\u003c\/strong\u003e, \u003cstrong data-end=\"8463\" data-start=\"8426\"\u003echeckpoint-inhibitor combinations\u003c\/strong\u003e, and \u003cstrong data-end=\"8483\" data-start=\"8469\"\u003eNAFLD\/NASH\u003c\/strong\u003e with \u003cstrong data-end=\"8521\" data-start=\"8489\"\u003eimmune and imaging endpoints\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8656\" data-start=\"8525\"\u003e\n\u003cp data-end=\"8656\" data-start=\"8527\"\u003e\u003cstrong data-end=\"8555\" data-start=\"8527\"\u003eBiomarker-guided therapy\u003c\/strong\u003e (e.g., \u003cstrong data-end=\"8574\" data-start=\"8563\"\u003emHLA-DR\u003c\/strong\u003e, lymphocyte counts, cytokine signatures) to select responders and time courses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8795\" data-start=\"8657\"\u003e\n\u003cp data-end=\"8795\" data-start=\"8659\"\u003e\u003cstrong data-end=\"8688\" data-start=\"8659\"\u003eCombination immunotherapy\u003c\/strong\u003e frameworks (with \u003cstrong data-end=\"8720\" data-start=\"8706\"\u003ePD-1\/PD-L1\u003c\/strong\u003e, \u003cstrong data-end=\"8743\" data-start=\"8722\"\u003eoncolytic viruses\u003c\/strong\u003e, \u003cstrong data-end=\"8761\" data-start=\"8745\"\u003eTLR agonists\u003c\/strong\u003e) to deepen antitumour immunity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8918\" data-start=\"8796\"\u003e\n\u003cp data-end=\"8918\" data-start=\"8798\"\u003e\u003cstrong data-end=\"8827\" data-start=\"8798\"\u003ePublic-health integration\u003c\/strong\u003e as \u003cstrong data-end=\"8843\" data-start=\"8831\"\u003eadjuvant\u003c\/strong\u003e for hard-to-immunize groups (elderly, CKD, cirrhosis, immunosuppressed).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9032\" data-start=\"8919\"\u003e\n\u003cp data-end=\"9032\" data-start=\"8921\"\u003e\u003cstrong data-end=\"8944\" data-start=\"8921\"\u003eMechanistic mapping\u003c\/strong\u003e of \u003cstrong data-end=\"8960\" data-start=\"8948\"\u003eTLR bias\u003c\/strong\u003e and downstream \u003cstrong data-end=\"8992\" data-start=\"8976\"\u003eIRF vs NF-κB\u003c\/strong\u003e balance to predict efficacy and safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"9037\" data-start=\"9034\"\u003e\n\u003ch3 data-end=\"9062\" data-start=\"9039\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9842\" data-start=\"9064\"\u003e\n\u003cli data-end=\"9177\" data-start=\"9064\"\u003e\n\u003cp data-end=\"9177\" data-start=\"9066\"\u003e\u003cstrong data-end=\"9103\" data-start=\"9066\"\u003eHepatology; Journal of Hepatology\u003c\/strong\u003e — Thymosin α1 in chronic viral hepatitis (monotherapy and combination).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9289\" data-start=\"9178\"\u003e\n\u003cp data-end=\"9289\" data-start=\"9180\"\u003e\u003cstrong data-end=\"9228\" data-start=\"9180\"\u003eVaccine; Human Vaccines \u0026amp; Immunotherapeutics\u003c\/strong\u003e — Adjuvant effects on seroconversion and T-cell responses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9418\" data-start=\"9290\"\u003e\n\u003cp data-end=\"9418\" data-start=\"9292\"\u003e\u003cstrong data-end=\"9342\" data-start=\"9292\"\u003eCancer Immunology Research; Annals of Oncology\u003c\/strong\u003e — Combinatorial immunotherapy data (checkpoint inhibitors, HCC regimens).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9525\" data-start=\"9419\"\u003e\n\u003cp data-end=\"9525\" data-start=\"9421\"\u003e\u003cstrong data-end=\"9463\" data-start=\"9421\"\u003eCritical Care; Intensive Care Medicine\u003c\/strong\u003e — Reversal of immunoparesis in sepsis and critical illness.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9633\" data-start=\"9526\"\u003e\n\u003cp data-end=\"9633\" data-start=\"9528\"\u003e\u003cstrong data-end=\"9581\" data-start=\"9528\"\u003eGerontology; Mechanisms of Ageing and Development\u003c\/strong\u003e — Immunosenescence trials and infection outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9739\" data-start=\"9634\"\u003e\n\u003cp data-end=\"9739\" data-start=\"9636\"\u003e\u003cstrong data-end=\"9694\" data-start=\"9636\"\u003eBone Marrow Transplantation; Supportive Care in Cancer\u003c\/strong\u003e — Onco-hematology supportive-care studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9842\" data-start=\"9740\"\u003e\n\u003cp data-end=\"9842\" data-start=\"9742\"\u003e\u003cstrong data-end=\"9792\" data-start=\"9742\"\u003eHepatology Communications; Liver International\u003c\/strong\u003e — Early NAFLD\/NASH investigations and biomarkers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684853576018,"sku":null,"price":65.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Thymosin_alpha-1_10mg.png?v=1770834863","url":"https:\/\/sciencepeptideslab.com\/products\/thymosin-alpha-1-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}